Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2005

01-01-2005 | Report

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

Authors: Gunter von Minckwitz, Walter Jonat, Peter Fasching, Andreas du Bois, Ulrich Kleeberg, Hans-Joachim Lück, Erika Kettner, Jörn Hilfrich, Wolfgang Eiermann, Julie Torode, Andreas Schneeweiss

Published in: Breast Cancer Research and Treatment | Issue 2/2005

Login to get access
Metadata
Title
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
Authors
Gunter von Minckwitz
Walter Jonat
Peter Fasching
Andreas du Bois
Ulrich Kleeberg
Hans-Joachim Lück
Erika Kettner
Jörn Hilfrich
Wolfgang Eiermann
Julie Torode
Andreas Schneeweiss
Publication date
01-01-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-1720-2

Other articles of this Issue 2/2005

Breast Cancer Research and Treatment 2/2005 Go to the issue

Erratum

Breast hamartoma: A Case Report

Report

Ultrasound criteria for ductal invasive breast cancer are modified by age, tumor size, and axillary lymph node status

Report

Breast hamartoma: a case report

Brief communication

Inhibition of metastasis by inhibition of tumor-derived CCL5

Report

cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion

Report

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits